The European market for cannabinoid-based therapies faces challenges due to varying regulations, healthcare systems, and a historical research backlog regarding the therapeutic potential of cannabis. This results in inconsistent access to reliable cannabinoid treatments and wellness products across different regions.

Sanity Group addresses these challenges by developing and distributing cannabinoid-based pharmaceuticals and wellness products tailored to the specific needs of the European market. The company focuses on research and development, utilizing precise extraction methods to ensure consistent dosing and efficacy. Through its Sanity Medical division, the company develops and distributes innovative cannabis pharmaceuticals, while Sanity Care focuses on superior consumer products based on non-psychoactive cannabinoids. Sanity Science conducts R&D and produces high-quality extracts for all operational business areas.

Development of cannabinoid-based pharmaceuticals adhering to GMP standards

Distribution of medicinal cannabis products to pharmacies and clinical institutions through Vayamed

Development of consumer CBD products through vaay

R&D projects focused on exploring the therapeutic potential of cannabinoids

High-quality cannabinoid extracts for pharmaceutical and consumer applications

Medical and political advisory boards to inform strategic direction and address perception issues

Partnerships with production facilities in Europe, South Africa, and Canada

Sanity Group targets patients seeking cannabinoid-based therapies, healthcare professionals, and consumers interested in cannabinoid-based wellness products in the European market.